JP2006515747A - 免疫関連疾患の治療のための組成物と方法 - Google Patents

免疫関連疾患の治療のための組成物と方法 Download PDF

Info

Publication number
JP2006515747A
JP2006515747A JP2004550183A JP2004550183A JP2006515747A JP 2006515747 A JP2006515747 A JP 2006515747A JP 2004550183 A JP2004550183 A JP 2004550183A JP 2004550183 A JP2004550183 A JP 2004550183A JP 2006515747 A JP2006515747 A JP 2006515747A
Authority
JP
Japan
Prior art keywords
polypeptide
pro
antibody
acid sequence
pro polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2004550183A
Other languages
English (en)
Japanese (ja)
Inventor
ヒラリー クラーク，
ジル ショーンフェルド，
ルッカレン， メンノ バン
ピー．， ミッキー ウィリアムズ，
ウィリアム， アイ． ウッド，
トーマス， ディー． ウー，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of JP2006515747A publication Critical patent/JP2006515747A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Biotechnology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Analytical Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Neurology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
JP2004550183A 2002-11-01 2003-10-30 免疫関連疾患の治療のための組成物と方法 Pending JP2006515747A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42339402P 2002-11-01 2002-11-01
PCT/US2003/034312 WO2004041170A2 (en) 2002-11-01 2003-10-30 Compositions and methods for the treatment of immune related diseases

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2009263287A Division JP2010162017A (ja) 2002-11-01 2009-11-18 免疫関連疾患の治療のための組成物と方法

Publications (1)

Publication Number Publication Date
JP2006515747A true JP2006515747A (ja) 2006-06-08

Family

ID=32312654

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2004550183A Pending JP2006515747A (ja) 2002-11-01 2003-10-30 免疫関連疾患の治療のための組成物と方法
JP2009263287A Pending JP2010162017A (ja) 2002-11-01 2009-11-18 免疫関連疾患の治療のための組成物と方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2009263287A Pending JP2010162017A (ja) 2002-11-01 2009-11-18 免疫関連疾患の治療のための組成物と方法

Country Status (6)

Country Link
US (3) US20060263774A1 (enExample)
EP (1) EP1578367A4 (enExample)
JP (2) JP2006515747A (enExample)
AU (2) AU2003284357A1 (enExample)
CA (1) CA2503390A1 (enExample)
WO (1) WO2004041170A2 (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007145326A1 (ja) * 2006-06-15 2007-12-21 Riken 炎症性疾患の判定方法
JP2017520271A (ja) * 2014-04-18 2017-07-27 ▲煙▼台聚▲傑▼生物工程有限公司 １５種類の男性生殖関連タンパク質またはその組み合わせの使用
JP2023511358A (ja) * 2020-01-21 2023-03-17 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 線維化、肥大または心不全の処置または予防における使用のための骨髄由来増殖因子
JP2023085301A (ja) * 2017-05-24 2023-06-20 テリス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 高アンモニア血症を治療するためのグルタミン合成酵素の使用

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070014787A1 (en) * 1998-07-15 2007-01-18 Human Genome Sciences, Inc. 71 human secreted proteins
US7479555B2 (en) 1999-07-21 2009-01-20 Ceres, Inc. Polynucleotides having a nucleotide sequence that encodes a polypeptide having MOV34 family activity
US8044259B2 (en) 2000-08-03 2011-10-25 The Regents Of The University Of Michigan Determining the capability of a test compound to affect solid tumor stem cells
US6984522B2 (en) 2000-08-03 2006-01-10 Regents Of The University Of Michigan Isolation and use of solid tumor stem cells
US7534429B2 (en) 2000-11-29 2009-05-19 Hoffmann-La Roche Inc. Cytotoxicity mediation of cells evidencing surface expression of CD63
US7431923B2 (en) 2005-01-03 2008-10-07 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of CD63
US7442777B2 (en) 2000-11-29 2008-10-28 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of CD63
AU2002332929A1 (en) 2001-09-07 2003-03-24 Bristol-Myers Squibb Company Polynucleotide encoding a novel human g-protein coupled receptor, hgprbmy39
WO2004013311A2 (en) * 2002-08-06 2004-02-12 Diadexus, Inc. Compositions and methods relating to ovarian specific genes and proteins
US20050037946A1 (en) * 2003-01-13 2005-02-17 Millennium Pharmaceuticals, Inc. Methods and compositions for treating cardiovascular disease using 1722, 10280, 59917, 85553, 10653, 9235, 21668, 17794, 2210, 6169, 10102, 21061, 17662, 1468, 12282, 6350, 9035, 1820, 23652, 7301, 8925, 8701, 3533, 9462, 9123, 12788, 17729, 65552, 1261, 21476, 33770, 9380, 2569654, 33556, 53656, 44143, 32612, 10671, 261, 44570, 41922, 2552, 2417, 19319, 43969, 8921, 8993, 955, 32345, 966, 1920, 17318, 1510, 14180, 26005, 554, 16408, 42028, 112091, 13886, 13942, 1673, 54946 or 2419
WO2004083388A2 (en) 2003-03-14 2004-09-30 Bristol-Myers Squibb Company Polynucleotide encoding a novel human g-protein coupled receptor variant of hm74, hgprbmy74
ITRM20030149A1 (it) 2003-04-02 2004-10-03 Giuliani Spa Oligonucleotidi (odn) antisenso per smad7 e loro usi in campo medico
WO2005019258A2 (en) * 2003-08-11 2005-03-03 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
US20050186577A1 (en) 2004-02-20 2005-08-25 Yixin Wang Breast cancer prognostics
US7306923B2 (en) * 2004-06-14 2007-12-11 Galapagos N.V. Methods for identification, and compounds useful for the treatment of degenerative & inflammatory diseases
CA2570483A1 (en) * 2004-06-21 2006-01-05 Exelixis, Inc. Pgds as modifiers of the pten pathway and methods of use
JPWO2006006477A1 (ja) * 2004-07-09 2008-04-24 国立大学法人三重大学 骨疾患又は関節疾患に関与するポリペプチド及びそのｄｎａ
EP1768690A4 (en) * 2004-07-16 2009-09-09 Val Chum S E C METHODS OF USING NUCLEAR ANTIGEN OF LAMIN B1, FRAGMENTS AND COMPOSITIONS THEREOF TO PREVENT OR TREAT A THROMBOTIC EVENT
EP1835933A4 (en) * 2005-01-04 2015-01-07 Yeda Res & Dev HSP60, HSP60-PEPTIDES AND T-CELL VACCINES FOR IMMUNOMODULATION
AU2006216715A1 (en) 2005-02-22 2006-08-31 Ceres Inc. Modulating plant alkaloids
EP1851543A2 (en) 2005-02-24 2007-11-07 Compugen Ltd. Novel diagnostic markers, especially for in vivo imaging, and assays and methods of use thereof
GB0510627D0 (en) 2005-05-25 2005-06-29 Avidex Ltd Polypeptides
US8124839B2 (en) 2005-06-08 2012-02-28 Ceres, Inc. Identification of terpenoid-biosynthesis related regulatory protein-regulatory region associations
EP1926747A1 (en) * 2005-08-12 2008-06-04 Schering Corporation Mcp1 fusions
GB0519376D0 (en) * 2005-09-23 2005-11-02 Astrazeneca Ab Diagnostic method
US8110184B2 (en) * 2005-09-30 2012-02-07 University Of Kentucky Research Foundation Ex vivo and in vivo methods and related compositions for generating hematopoietic stem cell populations
AU2006308847C1 (en) 2005-10-31 2012-05-10 Oncomed Pharmaceuticals, Inc. Compositions and methods for treating and diagnosing cancer
US20070192885A1 (en) * 2006-01-26 2007-08-16 Daniel Chelsky TAT-039 and methods of assessing and treating cancer
US8252547B2 (en) 2006-03-20 2012-08-28 Japan Science And Technology Agency In vitro control of protein synthesis in mammalian cells by IP3 receptor-binding protein
JP5146944B2 (ja) * 2006-03-20 2013-02-20 独立行政法人理化学研究所 Ｉｐ３受容体結合タンパク質による細胞内標的分子の制御
EP2006380A4 (en) 2006-03-23 2010-08-11 Kyowa Hakko Kirin Co Ltd AGONIST ANTIBODY AGAINST THE HUMAN THROMBOPOIETINE RECEPTOR
US20070237713A1 (en) 2006-04-04 2007-10-11 Fan Rong A PCan065 Antibody Compositions and Methods of Use
PL2032166T3 (pl) * 2006-06-13 2013-09-30 Oncomed Pharm Inc Kompozycje i sposoby diagnozowania i leczenia nowotworów
FR2908654B1 (fr) 2006-11-20 2014-04-04 Oreal Utilisation cosmetique de proteines de type chitinase
EP2097138A2 (en) * 2006-11-29 2009-09-09 Medical Research Council Assay
WO2008079406A2 (en) * 2006-12-19 2008-07-03 Genentech, Inc. Gene expression markers for inflammatory bowel disease
EP2106439B1 (en) 2007-01-24 2014-11-12 The Regents of the University of Michigan Compositions and methods for treating and diagnosing pancreatic cancer
JP5618544B2 (ja) 2007-01-24 2014-11-05 オンコメッドファーマシューティカルズ インコーポレイテッド 癌の診断および処置のための組成物および方法
WO2008092214A1 (en) * 2007-02-02 2008-08-07 Minomic International Limited Biomarkers for diabetes
US20090208491A1 (en) * 2007-02-14 2009-08-20 Austin Gurney Compositions and Methods for Diagnosing and Treating Cancer
JP5378202B2 (ja) * 2007-03-15 2013-12-25 株式会社リバース・プロテオミクス研究所 脳・神経に特異的あるいは神経分化に特異的なバイオマーカー
US8545888B2 (en) * 2007-06-14 2013-10-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Tendon stem cells
CN101835799A (zh) * 2007-08-24 2010-09-15 麦莱克萨有限公司 超敏反应调节剂
JP2009055838A (ja) * 2007-08-31 2009-03-19 Nipro Corp 融合タンパク質、該融合タンパク質に関連する遺伝子、ベクター、形質転換体及び抗炎症性医薬組成物
JOP20190083A1 (ar) 2008-06-04 2017-06-16 Amgen Inc بولي ببتيدات اندماجية طافرة لـfgf21 واستخداماتها
US9132189B2 (en) 2008-07-08 2015-09-15 Oncomed Pharmaceuticals, Inc. Notch1 binding agents and methods of use thereof
US8834875B2 (en) 2010-01-13 2014-09-16 Oncomed Pharmaceuticals, Inc. Notch1 binding agents and methods of use thereof
CN102316897B (zh) 2008-07-08 2014-11-05 昂考梅德药品有限公司 Notch结合剂和拮抗剂及其应用方法
EP2358749B1 (en) 2008-10-10 2018-07-18 Amgen, Inc Fgf21 mutants and uses thereof
AU2009308707A1 (en) 2008-10-31 2010-05-06 Biogen Idec Ma Inc. LIGHT targeting molecules and uses thereof
RU2520748C2 (ru) * 2008-12-04 2014-06-27 Санофи Способы и применения, включающие гемсвязывающий белок 1
WO2010067308A2 (en) 2008-12-08 2010-06-17 Compugen Ltd. Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics
BRPI1011404B1 (pt) 2009-05-05 2022-05-03 Amgen Inc Polipeptídeos mutantes fgf21, polipeptídeo de fusão, multímero, composição farmacêutica, ácido nucleico isolado, vetor e célula hospedeira
AU2010246038A1 (en) 2009-05-05 2011-12-01 Amgen Inc. FGF21 mutants and uses thereof
WO2010129890A2 (en) * 2009-05-08 2010-11-11 Virginia Tech Intellectual Properties, Inc. Compounds and methods for inhibiting platelet aggregation
WO2010141999A1 (en) * 2009-06-12 2010-12-16 The University Of Queensland Agents and methods for diagnosing and treating ankylosing spondylitis
EP2443145A1 (en) 2009-06-17 2012-04-25 Amgen, Inc Chimeric fgf19 polypeptides and uses thereof
WO2011053982A2 (en) 2009-11-02 2011-05-05 University Of Washington Therapeutic nuclease compositions and methods
JP2013512672A (ja) * 2009-12-02 2013-04-18 アムジエン・インコーポレーテツド ヒトＦＧＦＲ１ｃ、ヒトβ−クロト−、ならびにヒトＦＧＦＲ１ｃおよびヒトβ−クロト−の両方に結合する結合タンパク質
UA109888C2 (uk) * 2009-12-07 2015-10-26 ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ
EP2517049B1 (en) 2010-01-28 2014-01-08 Canon Kabushiki Kaisha Scintillator crystal body, method for manufacturing the same, and radiation detector
CA2695337A1 (en) * 2010-03-04 2011-09-04 Ian De Belle Compositions and methods for inhibition of hiv
US8524217B2 (en) 2010-05-11 2013-09-03 Merck Sharp & Dohme Corp. MCP1-Ig fusion variants
EP2975134A3 (en) 2010-07-22 2016-02-24 Shire Human Genetic Therapies, Inc. Crystal structure of human alpha-n-acetylglucosaminidase
KR101650995B1 (ko) 2010-11-08 2016-08-25 노파르티스 아게 Ｃｘｃｒ２ 결합 폴리펩티드
IT1406405B1 (it) * 2010-12-27 2014-02-21 Univ Roma Molecole peptidiche per il trattamento di patologie mitocondriali
WO2012090150A2 (en) * 2010-12-27 2012-07-05 Compugen Ltd New cell-penetrating peptides and uses thereof
JP6063450B2 (ja) 2011-04-29 2017-01-18 ユニヴァーシティ オブ ワシントン 治療用ヌクレアーゼ組成物および方法
US20150133322A1 (en) * 2011-05-13 2015-05-14 Inserm (Institut National De La Sante Et De La Recherche Medicale Method for the diagnosis of early rheumatoid arthritis
US9328174B2 (en) 2012-05-09 2016-05-03 Novartis Ag Chemokine receptor binding polypeptides
BR112015010436A2 (pt) 2012-11-07 2017-08-22 Pfizer Anticorpos anti-notch3 e conjugados anticorpo-fármaco
WO2014100689A1 (en) 2012-12-21 2014-06-26 Aveo Pharmaceuticals, Inc. Anti-gdf15 antibodies
US9944700B2 (en) 2013-03-13 2018-04-17 Novartis Ag Notch2 binding molecules for treating respiratory diseases
HRP20192080T1 (hr) 2013-10-31 2020-02-07 Resolve Therapeutics, Llc Terapeutske fuzije nukleaza-albumine i postupci
RU2016128557A (ru) * 2013-12-29 2018-02-01 Кьюрлаб Онколоджи, Инк. МЕТОДЫ И КОМПОЗИЦИИ, СВЯЗАННЫЕ С p62 / SQSTM1, ДЛЯ ЛЕЧЕНИЯ И ПРОФИЛАКТИКИ ЗАБОЛЕВАНИЙ, АССОЦИИРОВАННЫХ С ВОСПАЛЕНИЕМ
SG11201700901SA (en) 2014-08-08 2017-03-30 Alector Llc Anti-trem2 antibodies and methods of use thereof
GB201508025D0 (en) 2015-05-11 2015-06-24 Ucl Business Plc Fabry disease gene therapy
BR112018071686A2 (pt) * 2016-04-22 2019-02-19 Vaccinex, Inc. exibição de proteínas integrais de membrana em vírions extracelulares envelopados de poxvírus
DK3478830T3 (da) 2016-07-01 2024-05-21 Resolve Therapeutics Llc Optimerede binucleasefusioner og metoder
KR102033215B1 (ko) * 2016-07-05 2019-10-16 성균관대학교산학협력단 건선 유발 동물 모델 및 이의 용도
GB201700567D0 (en) 2017-01-12 2017-03-01 Genagon Therapeutics Ab Therapeutic agents
US11629340B2 (en) 2017-03-03 2023-04-18 Obsidian Therapeutics, Inc. DHFR tunable protein regulation
HRP20230675T1 (hr) 2017-08-03 2023-09-29 Alector Llc Anti-trem2 protutijela i postupci njihove uporabe
JP7374091B2 (ja) 2017-08-22 2023-11-06 サナバイオ， エルエルシー 可溶性インターフェロン受容体およびその使用
US12274733B2 (en) 2018-09-28 2025-04-15 President And Fellows Of Harvard College Cellular reprogramming to reverse aging and promote organ and tissue regeneration
AU2019347666B2 (en) 2018-09-28 2025-10-02 President And Fellows Of Harvard College Cellular reprogramming to reverse aging and promote organ and tissue regeneration
US20210388345A1 (en) * 2018-10-22 2021-12-16 Roche Sequencing Solutions, Inc. Profiling of rheumatoid arthritis autoantibody repertoire and peptide classifiers therefor
WO2020178426A1 (en) * 2019-03-07 2020-09-10 INSERM (Institut National de la Santé et de la Recherche Médicale) New vaccinal strategy to prevent or treat rheumatoid arthritis
US20250270278A1 (en) * 2020-12-07 2025-08-28 The Research Foundation For The State University Of New York Methods of making water-soluble protein formed in a bacterial expression system, compositions, and methods of use thereof
US12252518B2 (en) 2023-01-06 2025-03-18 Life Biosciences, Inc. Methods of treating non-arteritic anterior ischemic optic neuropathy
WO2024231931A1 (en) * 2023-05-08 2024-11-14 Canopy Immuno-Therapeutics Ltd. Ig-like fusion proteins for treating immune thrombocytopenia
US20250108088A1 (en) * 2023-10-02 2025-04-03 Matice BioSciences, Inc. Regenerative peptides and methods for use thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000012525A1 (en) * 1998-08-27 2000-03-09 Quark Biotech, Inc. Sequences characteristic of hypoxia-regulated gene transcription
JP2001526892A (ja) * 1997-12-23 2001-12-25 イミュネックス・コーポレーション Ｓｉｇｉｒｒｄｎａおよびポリペプチド

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223425A (en) * 1987-04-02 1993-06-29 The Beth Israel Hospital Association DNA encoding human adipsin with complement D activity
EP0382720B1 (en) * 1987-04-02 1992-09-09 The Beth Israel Hospital Association Diagnosing obesity caused by a genetic abnormality and method of therapeutically treating genetically caused obesity
CA2044940A1 (en) * 1991-06-10 1992-12-11 Inder M. Verma Transdominant negative proto-oncogene
US6956107B2 (en) * 1998-02-20 2005-10-18 Tanox, Inc. Inhibitors of complement activation
KR20010103046A (ko) * 1999-03-08 2001-11-17 제넨테크, 인크. 면역 관련 질환 치료용 조성물 및 치료 방법
US20030199103A1 (en) * 1999-06-03 2003-10-23 Curagen Corporation Novel amino acid sequences for human epidermal growth factor-like polypeptides
IL151865A0 (en) * 2000-03-31 2003-04-10 Genentech Inc Compositions and methods for detecting and quantifying gene expression
US6812339B1 (en) * 2000-09-08 2004-11-02 Applera Corporation Polymorphisms in known genes associated with human disease, methods of detection and uses thereof
US6867189B2 (en) * 2001-07-26 2005-03-15 Genset S.A. Use of adipsin/complement factor D in the treatment of metabolic related disorders

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001526892A (ja) * 1997-12-23 2001-12-25 イミュネックス・コーポレーション Ｓｉｇｉｒｒｄｎａおよびポリペプチド
WO2000012525A1 (en) * 1998-08-27 2000-03-09 Quark Biotech, Inc. Sequences characteristic of hypoxia-regulated gene transcription

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007145326A1 (ja) * 2006-06-15 2007-12-21 Riken 炎症性疾患の判定方法
JP2007330166A (ja) * 2006-06-15 2007-12-27 Institute Of Physical & Chemical Research 炎症性疾患の判定方法
US8158351B2 (en) 2006-06-15 2012-04-17 Riken Method for determining inflammatory disease
JP2017520271A (ja) * 2014-04-18 2017-07-27 ▲煙▼台聚▲傑▼生物工程有限公司 １５種類の男性生殖関連タンパク質またはその組み合わせの使用
JP2023085301A (ja) * 2017-05-24 2023-06-20 テリス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 高アンモニア血症を治療するためのグルタミン合成酵素の使用
JP7688926B2 (ja) 2017-05-24 2025-06-05 テリス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 高アンモニア血症を治療するためのグルタミン合成酵素の使用
US12359184B2 (en) 2017-05-24 2025-07-15 Thoeris Gmbh Use of glutamine synthetase for treating hyperammonemia
JP2023511358A (ja) * 2020-01-21 2023-03-17 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 線維化、肥大または心不全の処置または予防における使用のための骨髄由来増殖因子
JP7777532B2 (ja) 2020-01-21 2025-11-28 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 線維化、肥大または心不全の処置または予防における使用のための骨髄由来増殖因子

Also Published As

Publication number Publication date
EP1578367A2 (en) 2005-09-28
US20060263774A1 (en) 2006-11-23
AU2010212279A1 (en) 2010-09-02
US20120083420A1 (en) 2012-04-05
US20090098131A1 (en) 2009-04-16
JP2010162017A (ja) 2010-07-29
WO2004041170A2 (en) 2004-05-21
EP1578367A4 (en) 2012-05-02
WO2004041170A9 (en) 2010-01-21
CA2503390A1 (en) 2004-05-21
AU2003284357A1 (en) 2004-06-07

Similar Documents

Publication Publication Date Title
JP5401001B2 (ja) 免疫関連疾患の治療のための新規組成物と方法
JP2006515747A (ja) 免疫関連疾患の治療のための組成物と方法
JP4901747B2 (ja) 免疫関連疾患の治療のための新規組成物と方法
JP2006516094A (ja) ナチュラルキラー細胞関連疾患の治療のための組成物と方法
JP2012254093A (ja) 免疫関連疾患の治療のための新規組成物と方法
JP2010220614A (ja) 免疫関連疾患の治療のための組成物と方法
JP2006513700A (ja) 乾癬の治療のための新規組成物と方法
JP2011172580A (ja) 免疫関連疾患の治療のための新規組成物と方法
JP2010088434A (ja) 免疫関連疾患の治療のための新規組成物と方法
JP2006515167A (ja) 免疫関連疾患の治療のための新規組成物と方法
JP2013240329A (ja) 全身性エリテマトーデスの治療のための組成物と方法
JP2013051961A (ja) 免疫関連疾患の治療のための新規組成物と方法
JP2010057491A (ja) 乾癬の治療のための新規組成物と方法
JP2008301810A (ja) 免疫関連疾患を治療するための組成物及び方法
JP2006521810A (ja) 免疫関連疾患の治療のための新規組成物と方法
JP2013048621A (ja) 免疫関連疾患の治療のための組成物と方法
JP2005519590A (ja) 免疫関連疾患の治療のための組成物及び方法
JP2006515748A (ja) リウマチ様関節炎の治療のための組成物と方法
JP3988821B2 (ja) 免疫関連疾患を治療するための組成物及び方法
JP2006519582A (ja) 乾癬の治療のための新規組成物と方法
JP2006511210A (ja) 免疫関連疾患の治療のための新規組成物と方法

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20061026

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090818

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20091118

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100112

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100409

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100416

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100512

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100519

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100614

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100621

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100712

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110412